Arti Ahluwalia

Arti Ahluwalia was born in Kenya and educated in the UK. She has a B.Sc. Physics from Univerisity of Bath,  M.Sc. in Instrumentation and Analytical Science from the University of Manchester (formerly UMIST), UK and a Ph.D. in Bioengineering from the Polytechnic of Milan, Italy. Her research interests are in in-vitro models of integrative pathophysiology and associated innovative materials and advanced cell culture systems. She is also involved in capacity building in the field of Biomedical Engineering, in association with UNECA, FABLAB Pisa and ABEC (the African Biomedical Engineering Consortium).


Associate Professor of Bioengineering at the Department of Information Engineering, School of Engineering, University of Pisa, and affiliated with the Research Center "E. Piaggio", where she heads the BioModels Group. Also an associate of the National Council of Research Institute of Clinical Physiology (CNR-IFC), heading the NanoBioscopy Lab. Although highly multidisciplinary in nature, her research has centered on the interaction between biological systems and man-made devices or structures focused on the creation of organ and system models in-vitro using soft and smart materials, cells and tissue derivatives, cell imaging and intelligent bioreactor design as a way towards understanding tissue cross talk and how this cross talk is used to orchestrate systemic physiology. The applications span from disease models to in-vitro alternatives to animal testing. In this context, her research experience encompasses cellular biotechnology, biomolecular films, surface engineering, and biosensing to microfabrication and biomaterials for tissue engineering. In particular, the work on organ models, sensors, biosensors and tissue engineering is undertaken within the CNR-IFC, taking full advantage of the presence of the skillful medical staff and ample cell culture facilities. Author of over 100 peer-reviewed publications and of several patents on microfabrication and on microfabricated  multicompartment bioreactors, now commercial products of 2 companies (Kirkstall Ltd, IVTech srl.) she co-founded. Current projects are on tissue regeneration (ReLiver), biosensing, robots for autism, bioreactors, in-vitro models of metabolic disease and ageing (MIND) and nanotoxicology (InLiveTox).